Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 938 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Screening and follow up Clear all
Active, not recruiting No phase listed Observational

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

NCT05987189
View directory record Official record
Conditions
Lung Cancer
Interventions
Small RNA-based lung cancer assay
Diagnostic Test
Lead sponsor
Hummingbird Diagnostics
Industry
Eligibility
50 Years to 80 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Atlanta, Georgia • Baton Rouge, Louisiana • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 1:30 PM EDT
Completed Not applicable Interventional Results available

Perioperative Blood Pressure Screening to Improve Long-term Cardiovascular Health

NCT03634813
View directory record Official record
Conditions
Blood Pressure
Interventions
High Blood Pressure Monitor, Usual Care
Device · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 15, 2026, 1:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)

NCT06688396
View directory record Official record
Conditions
Dilated Cardiomyopathy, Heart Failure, Heart Disease
Interventions
Mobile 6L AI-EKG Screening
Device
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 15, 2026, 1:30 PM EDT
Recruiting Phase 3 Interventional

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

NCT03567889
View directory record Official record
Conditions
Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
Interventions
Daromun, Surgery, Adjuvant therapy
Drug · Procedure
Lead sponsor
Philogen S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
19
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 15, 2026, 1:30 PM EDT
Terminated Not applicable Interventional Results available

Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

NCT00870818
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
Diagnostic Test · Behavioral
Lead sponsor
MacroGenics
Industry
Eligibility
10 Years to 37 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 15, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

NCT01382238
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
Dolutegravir 50 mg tablet, Dolutegravir 50 mg oral granules
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Oct 15, 2026, 1:30 PM EDT
Recruiting No phase listed Observational

Comparison of Conspicuity of Masses and Architectural Distortions Between Wide- and Narrow-angle Digital Breast Tomosynthesis Systems

NCT06373354
View directory record Official record
Conditions
Architectural Distortions, Breast Tomosynthesis
Interventions
Digital Breast Tomosynthesis (DBT)
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 1:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

NCT04867954
View directory record Official record
Conditions
Cirrhosis, Liver, Gastroesophageal Varices, Fontan Procedure
Interventions
Ensure Plus®, Pre-clinical validation contrast enhanced MRI, Clinical validation MRI, Pre-clinical validation contrast enhanced MRI + fasting
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 15, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Substance Treatment and HIV Testing and Referral System

NCT01488630
View directory record Official record
Conditions
Substance Abuse
Interventions
STaRS
Other
Lead sponsor
Polaris Health Directions
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 15, 2026, 1:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma

NCT06327477
View directory record Official record
Conditions
Retroperitoneal Sarcoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy, Resection, Spatially-fractionated Radiation Therapy
Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 15, 2026, 1:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

E-Tailored Pain Management Support for Dementia Family Caregivers: Feasibility of the PACE-app

NCT07032350
View directory record Official record
Conditions
Care Giving Burden, Dementia, Chronic Pain, Pain Management, Palliative Care
Interventions
Web-based pain management support tool, Usual Pain Management Care
Other · Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 15, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

Tisagenlecleucel In Primary CNS Lymphoma

NCT04134117
View directory record Official record
Conditions
Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma
Interventions
Tisagenlecleucel
Biological
Lead sponsor
Matthew J. Frigault, M.D.
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 15, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT02145091
View directory record Official record
Conditions
Healthy
Interventions
Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 15, 2026, 1:30 PM EDT
Completed Not applicable Interventional Results available

Caregiver Outcomes of Alzheimer's Disease Screening

NCT03300180
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Collaborative Dementia Care Program, Screening Only
Behavioral · Other
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
1,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 15, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Bioequivalence of a Combined Formulated Tablet

NCT01622790
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 15, 2026, 1:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Implementation of Adverse Childhood Experiences (ACEs) Policy

NCT04916587
View directory record Official record
Conditions
Adverse Childhood Experiences
Interventions
Implementation Strategy of ACEs Screenings, Usual Care
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Years to 5 Years
Enrollment
7,645 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Desert Hot Springs, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 15, 2026, 1:30 PM EDT
Completed Not applicable Interventional Results available

Community Trial in the Cherokee Nation

NCT04839978
View directory record Official record
Conditions
Opioid Abuse
Interventions
Connect Program, Communities Mobilizing for Change and Action (CMCA)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
15 Years to 17 Years
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Tahlequah, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 15, 2026, 1:30 PM EDT
Recruiting Phase 1 Interventional

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

NCT05801913
View directory record Official record
Conditions
High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Leukapheresis, Lymphodepletion Therapy, Magnetic Resonance Imaging, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Positron Emission Tomography, X-Ray Imaging
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 15, 2026, 1:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

NCT04576117
View directory record Official record
Conditions
Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma, Refractory WHO Grade 1 Glioma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Selumetinib Sulfate, Vinblastine Sulfate
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 25 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
91
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 15, 2026, 1:30 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

NCT01186991
View directory record Official record
Conditions
Breast Cancer
Interventions
Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
23
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 15, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Results available

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

NCT01013649
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7
Interventions
3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine, Chemotherapy, Computed Tomography, Erlotinib Hydrochloride, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Quality-of-Life Assessment, X-Ray Imaging
Radiation · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
678
States / cities
Mobile, Alabama • Anchorage, Alaska • Auburn, California + 438 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 15, 2026, 1:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)

NCT06730555
View directory record Official record
Conditions
HIV Infections
Interventions
ACCESS Intervention, Control Group
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 15, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Results available

Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin

NCT04541355
View directory record Official record
Conditions
Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Lip and Oral Cavity Cancer AJCC v8, Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Cisplatin, Hearing Handicap Inventory for Adults - Screening, Radiation Therapy, Sodium Thiosulfate
Drug · Other · Radiation
Lead sponsor
Hyunseok Kang, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 15, 2026, 1:30 PM EDT
Recruiting Not applicable Interventional

Brief Interventions to Reduce Comorbid Alcohol and Cannabis Misuse and Sleep Impairment in Young Adults (Rest-Up RCT)

NCT06736444
View directory record Official record
Conditions
Insomnia, Alcohol Use, Marijuana Use
Interventions
Brief Behavioral Therapy for Insomnia (BBTI), Brief Alcohol Screening and Intervention for College Students (BASICS), Attention Control
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 29 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 15, 2026, 1:30 PM EDT